Market Index Logo
Mobile Menu Icon
☆
Watchlist
Log in
Sign-up
Dorsavi Ltd (dvl) Logo

Dorsavi Ltd (DVL)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

DVL Chart

DVL's Principal Activity is the development and sale of innovative motion analysis technologies.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +175.84%
vs ASX 200 (1yr) +140.98%

Size

Market Capitalisation
ASX Rank 1984 of 2,560
Sector Rank 165 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies ANR / FFC / CDY
EPS -$0.008
DPS $0.00
NTA per share $0.01

Broker Consensus

DVL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Dorsavi Ltd (DVL) is a biotechnology company focused on medical research and development, supplying medical, sporting and occupational health and safety products, devices and services. DVL's products include ViPerform for Elite Sports, ViSafe for Occupational Health and Safety (OH&S) and ViMove for medical and physiotherapy.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Kew VIC 3101
Website www.dorsavi.com
Registry Computershare
Auditor Pitcher Partners
Date Listed 11 Dec 2013

Upcoming Calendar

Date Event
25/08/2021 Report (Prelim)
25/08/2021 Report (Annual)
22/02/2022 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Caroline Ann Elliott Non-Executive Director Nov 2017 Director Bio icon

Ms Caroline Ann Elliott

Non-Executive Director

Ms Elliot is currently a Director of the National Film and Sound Archive of Australia, St John's Ambulance Australia (Vic) and Wiltrust Nominees Pty Ltd. She has previously held non-executive director roles at Cell Therapies Pty Ltd, Peter MacCallum Cancer Centre and the Public Transport Ombudsman Limited. She is currently the Chief Executive Officer at apparel business, The Propel Group Pty Ltd, and was previously the CFO and Company Secretary at Optal Ltd. She also Chairs the Risk Committee.
Mr Gregory John Tweedly Non-Executive Director,Non-Executive Chairman Oct 2013 Director Bio icon

Mr Gregory John Tweedly

Non-Executive Director,Non-Executive Chairman

Mr Tweedly is a Director of Melbourne Health, Deputy Chair of Environment Protection Authority Victoria, Chair of the Personal Injury Education Foundation and was a Director and CEO of the Victorian WorkCover Authority (WorkSafe) from 2003 to 2012. Prior to joining WorkSafe, he was an executive with the Transport Accident Commission from 1996 to 2002 in senior roles which includes Chief Operating Officer. He was formerly a Director of the Emergency Services and Telecommunications Authority, Director of the Institute of Safety Compensation and Recovery Research, a Director of the Personal Injury Education Foundation, a Director and Chair of the Victorian Trauma Foundation, Chair of the Heads of Workers Compensation Authorities of Australia and New Zealand and Member of SafeWork Australia and its predecessor organisation.
Mr Brendan Case Company Secretary Oct 2013
Mr Ashraf Attia Non-Executive Director Jul 2008 Director Bio icon

Mr Ashraf Attia

Non-Executive Director

Mr Attia has had senior management experience in operations for over 30 years within the medical devices, biotechnology and diagnostics industries. He is currently Chief Executive Officer of Bionic Vision Technologies. He was recently Vice President of Asia Pacific, Middle East and Israel at TransMedics Inc, a company based in Boston, USA, and is carrying out work in the area of heart, lung and Liver organ transplants and preservation. He has held senior executive roles with global medical devices organizations and has expertise in the areas of commercialization, business development, clinical, regulatory, R&D, strategic marketing, sales and distribution management. He is a member of the Risk Committee.
Mr Michael Panaccio Non-Executive Director May 2008 Director Bio icon

Mr Michael Panaccio

Non-Executive Director

Mr Panaccio was formerly an Investment Manager with JAFCO Investment (Asia Pacific). Prior to JAFCO, he was Head of the Department of Molecular Biology at the Victorian Institute of Animal Sciences. He has previously been a director of technology businesses in Australia and the US including ImpediMed Ltd, SIRTeX Medical Ltd, Protagonist Therapeutic Inc and Energy Response Pty Ltd. Mr Panaccio is also a director of Starfish Ventures Pty Ltd. He is a member of the Risk Committee.
Dr Andrew James Ronchi Chief Executive Officer,Executive Director Feb 2008 Director Bio icon

Dr Andrew James Ronchi

Chief Executive Officer,Executive Director

Mr Ronchi was a practising physiotherapist both at an AFL club and in private practice. He has also been founding partner in two physiotherapy centres. He completed a PhD in Computer and Systems Engineering, investigating the reliability and validity of transducers for measuring lumbar spine movement.
Damian Connellan Chief Financial Officer N/A
David Erikson Chief Technical Officer N/A
Matthew May General Manager N/A
Show All Show more Icon

Director Transactions

DVL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
08/01/21 Ashraf Attia Issued 268,293 $0.041 $11,000 Issue of options
08/01/21 Caroline Elliott Issued 268,293 $0.04 $10,731 Issue of options
08/01/21 Gregory Tweedly Issued 366,299 $0.041 $15,018 Issue of options
08/01/21 Michael Panaccio Issued 268,293 $0.041 $11,000 Issue of options
23/12/20 Andrew Ronchi Issued 2,707,286 $0.028 $75,804 Issue of securities
20/11/20 Ashraf Attia Issued 115,380 $0.032 $3,692 Rights issue
20/11/20 Andrew Ronchi Issued 593,576 $0.032 $18,994 Rights issue
20/11/20 Caroline Elliott Issued 92,593 $0.032 $2,962 Rights issue
20/11/20 Gregory Tweedly Issued 203,782 $0.032 $6,521 Rights issue
20/11/20 Michael Panaccio Issued 323,530 $0.04 $13,001 Rights issue
07/10/20 Ashraf Attia Issued 323,530 $0.034 $11,000 Issue of options
07/10/20 Caroline Elliott Issued 323,530 $0.034 $11,000 Issue of options
07/10/20 Gregory Tweedly Issued 441,713 $0.034 $15,018 Issue of options
07/10/20 Michael Panaccio Issued 323,530 $0.034 $11,000 Issue of options
07/07/20 Ashraf Attia Issued 846,155 $0.001 $1,100 Director remuneration
07/07/20 Michael Panaccio Issued 846,155 $0.001 $1,100 Director remuneration
07/07/20 Gregory Tweedly Issued 1,155,249 $0.029 $33,502 Issue of options
07/04/20 Ashraf Attia Issued 1,100,001 $0.001 $1,100 Director remuneration
07/04/20 Caroline Elliott Issued 1,100,001 $0.001 $1,100 Director remuneration
07/04/20 Gregory Tweedly Issued 1,501,824 $0.01 $15,018 Director remuneration
07/04/20 Michael Panaccio Issued 1,100,001 $0.001 $1,100 Director remuneration
03/02/20 Andrew Ronchi Issued 3,703,704 $0.027 $100,000 Placement
03/02/20 Michael Panaccio Issued 9,259,259 $0.027 $249,500 Placement
03/02/20 Caroline Elliott Issued 370,370 $0.027 $10,000 Placement
03/02/20 Michael Panaccio Issued 9,259,259 $0.027 $249,499 Placement
03/02/20 Andrew Ronchi Issued 3,703,704 $0.027 $100,000 Placement
07/01/20 Caroline Elliott Issued 423,077 $0.026 $11,000 Issue of options
07/01/20 Gregory Tweedly Issued 577,625 $0.026 $15,018 Issue of options
07/01/20 Michael Panaccio Issued 423,077 $0.026 $11,000 Issue of options
07/01/20 Ashraf Attia Issued 423,077 $0.026 $11,000 Issue of options
07/01/20 Ashraf Attia Issued 423,077 $0.026 $11,000 Issue of options
07/01/20 Michael Panaccio Issued 423,077 $0.026 $11,000 Issue of options
30/12/19 Andrew Ronchi Buy +700,000 $0.028 $19,600 Participation in share purchase plan
30/12/19 Ashraf Attia Buy +180,000 $0.028 $5,040 Participation in share purchase plan
30/12/19 Michael Panaccio Buy +1,070,000 $0.028 $29,960 Participation in share purchase plan
30/12/19 Gregory Tweedly Buy +700,000 $0.028 $19,600 Participation in share purchase plan
06/12/19 Andrew Ronchi Expiry 24,000 $0.026 $624 As advised by the company
06/12/19 Andrew Ronchi Issued 63,000 $0.026 $1,638 Conversion of securities
06/12/19 Andrew Ronchi Issued 450,000 $0.026 $11,700 As advised by the company
06/12/19 Andrew Ronchi Exercise 63,000 $0.026 $1,638 Conversion of securities
04/12/19 Gregory Tweedly Issued 749,747 $0.026 $19,493 Issue of options
04/12/19 Michael Panaccio Issued 549,148 $0.026 $14,278 Issue of options
04/12/19 Caroline Elliott Issued 549,148 $0.026 $14,278 Issue of options
04/12/19 Ashraf Attia Issued 549,148 $0.026 $14,278 Issue of options
21/12/18 Michael Panaccio Issued 1,873,376 $0.058 $108,656 Rights issue
21/12/18 Ashraf Attia Issued 70,379 $0.058 $4,082 Rights issue
21/12/18 Andrew Ronchi Buy +3,200 $0.058 $186 As advised by the company
21/12/18 Michael Panaccio Buy +6,896,552 $0.058 $400,000 As advised by the company
08/10/18 Andrew Ronchi Expiry 138,750 $0.085 $11,794 As advised by the company
Show All Show more Icon

Director Interests

The current holdings of DVL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Ashraf Attia 08/01/2021 576,898 N/A 3,510,204 N/A
Gregory Tweedly 08/01/2021 1,018,911 N/A 4,792,457 N/A
Caroline Elliott 08/01/2021 N/A 462,963 3,510,204 N/A
Michael Panaccio 08/01/2021 N/A 99,627,870 3,510,204 N/A
Andrew Ronchi 23/12/2020 5,675,171 N/A N/A N/A
Show All Show more Icon

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Aug 13, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Starfish Technology Fund Ii Lp 60,597,345 26.18%
Starfish Technology Fund Ii Nominees A Pty Ltd 18,464,557 7.98%
Starfish Technology Fund Ii Nominees B Pty Ltd 18,464,557 7.98%
Ar Bsm Pty Ltd <Ar Bsm A/C> 7,021,814 3.03%
Bannaby Investments Pty Limited <Bannaby Super Fund A/C> 4,428,497 1.91%
Drnewnham Super Pty Ltd <Drn Superannuation Fund A/C> 4,231,516 1.83%
Tanarny Super Fund Pty Ltd <Tanarny Super Fund A/C> 3,703,704 1.60%
Ms Gabrielle Banay 3,233,482 1.40%
Andrew Ronchi 2,374,309 1.03%
Mrs Amity Brooke Johnson 2,000,000 0.86%
Damian Connellan 1,971,071 0.85%
Mr Shane Timothy Ball <The Ball A/C> 1,850,000 0.80%
Mr Sheng Sun 1,730,000 0.75%
Mr Brian Tully and Mrs Margaret Tully <Superannuation Fund A/C> 1,656,125 0.72%
Masto Pty Ltd <Micana Super Fund A/C> 1,625,129 0.70%
Mr Stuart Andrew Lewin 1,579,000 0.68%
Trujon Investment Holdings Pty Ltd <Trujon Super Fund A/C> 1,517,333 0.66%
Valence Holdings Pty Ltd The Pw & Cm Stinton <Superannuation Fund A/C> 1,486,991 0.64%
Mr Wai Kit Lee 1,278,920 0.55%
Daniel Ronchi 1,244,668 0.54%
Show All Show more Icon

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 41 187 196 627 222 1,273

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Starfish Technology Fund 2, LP 09/02/2021 102,875,786 29.41

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
09-02-21 Starfish Technology Fund 2, LP 1,055,865 35.20 29.41
11-12-20 Credit Suisse Holdings (Australia) Limited 5,764,226 5.33 7.26
10-12-20 Credit Suisse Holdings (Australia) Limited 15,911,645 -- 5.33
30-10-20 Starfish Technology Fund 2, LP 29,052,166 43.49 35.20

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
09-02-21 AR BSM Pty Ltd 13,803,027 5.96 --
14-12-20 Credit Suisse Holdings (Australia) Limited 21,675,871 7.26 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.013 30 June
2019 $0.05 28 June
2018 $0.12 29 June
2017 $0.29 28 June
2016 $0.32 28 June
2015 $0.27 30 June
2014 $0.46 30 June
Page Icon
DVL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download Secure Content Icon
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.